N K Ibrahim

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. ncbi request reprint Colitis in patients with breast carcinoma treated with taxane-based chemotherapy
    Zhiyong Li
    Division of Medical Oncology, Department of Medicine, The University of Texas MD Anderson Cancer Center, Houston 77030 4009, USA
    Cancer 101:1508-13. 2004
  2. pmc Phase I dose escalation pharmacokinetic assessment of intravenous humanized anti-MUC1 antibody AS1402 in patients with advanced breast cancer
    Mark D Pegram
    Division of Hematology Oncology, University of Miami Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, 1475 NW 12th Avenue Suite 3400 D8 4, Miami, FL 33136, USA
    Breast Cancer Res 11:R73. 2009
  3. ncbi request reprint Clinical development of the STn-KLH vaccine (Theratope)
    Nuhad K Ibrahim
    Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, Houston 77030 4009, USA
    Clin Breast Cancer 3:S139-43. 2003
  4. ncbi request reprint Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer
    Nuhad K Ibrahim
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 424, Houston, TX 77030 4009, USA
    J Clin Oncol 23:6019-26. 2005
  5. ncbi request reprint Phase I study of vinorelbine and docetaxel with granulocyte colony-stimulating factor support in the treatment of metastatic breast cancer
    Nuhad K Ibrahim
    Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, Houston 77030 4009, USA
    Cancer Invest 20:29-37. 2002
  6. ncbi request reprint Phase I-II vinorelbine (Navelbine) by continuous infusion in patients with metastatic breast cancer: cumulative toxicities limit dose escalation
    N K Ibrahim
    Division of Medicine, Department of Breast Medical Oncology, Box 56, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Cancer Invest 19:459-66. 2001
  7. ncbi request reprint Phase I study of vinorelbine and paclitaxel by 3-hour simultaneous infusion with and without granulocyte colony-stimulating factor support in metastatic breast carcinoma
    N K Ibrahim
    Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030 4009, USA
    Cancer 91:664-71. 2001
  8. ncbi request reprint Doxorubicin-based adjuvant chemotherapy in elderly breast cancer patients: the M.D. Anderson experience, with long-term follow-up
    N K Ibrahim
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Ann Oncol 11:1597-601. 2000
  9. ncbi request reprint The evolving role of specific estrogen receptor modulators (SERMs)
    N K Ibrahim
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, USA
    Surg Oncol 8:103-23. 1999
  10. ncbi request reprint Colitis associated with docetaxel-based chemotherapy in patients with metastatic breast cancer
    N K Ibrahim
    Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Lancet 355:281-3. 2000

Collaborators

Detail Information

Publications27

  1. ncbi request reprint Colitis in patients with breast carcinoma treated with taxane-based chemotherapy
    Zhiyong Li
    Division of Medical Oncology, Department of Medicine, The University of Texas MD Anderson Cancer Center, Houston 77030 4009, USA
    Cancer 101:1508-13. 2004
    ..The incidence, clinical presentation, and outcome of colitis in patients with breast carcinoma treated with taxane-based chemotherapy is not known...
  2. pmc Phase I dose escalation pharmacokinetic assessment of intravenous humanized anti-MUC1 antibody AS1402 in patients with advanced breast cancer
    Mark D Pegram
    Division of Hematology Oncology, University of Miami Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, 1475 NW 12th Avenue Suite 3400 D8 4, Miami, FL 33136, USA
    Breast Cancer Res 11:R73. 2009
    ....
  3. ncbi request reprint Clinical development of the STn-KLH vaccine (Theratope)
    Nuhad K Ibrahim
    Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, Houston 77030 4009, USA
    Clin Breast Cancer 3:S139-43. 2003
    ..Interim analysis from a current phase III trial has confirmed the safety of the STn-KLH vaccine, and the clinical outcome awaits the final analysis expected in 2003...
  4. ncbi request reprint Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer
    Nuhad K Ibrahim
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 424, Houston, TX 77030 4009, USA
    J Clin Oncol 23:6019-26. 2005
    ..ABI-007 is a novel nanoparticle, albumin-bound paclitaxel that is free of solvents. This multicenter phase II study was designed to evaluate the efficacy and safety of ABI-007 for the treatment of metastatic breast cancer (MBC)...
  5. ncbi request reprint Phase I study of vinorelbine and docetaxel with granulocyte colony-stimulating factor support in the treatment of metastatic breast cancer
    Nuhad K Ibrahim
    Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, Houston 77030 4009, USA
    Cancer Invest 20:29-37. 2002
    ..The aim of this study was to determine the MTD of vinorelbine and docetaxel given in combination with G-CSF...
  6. ncbi request reprint Phase I-II vinorelbine (Navelbine) by continuous infusion in patients with metastatic breast cancer: cumulative toxicities limit dose escalation
    N K Ibrahim
    Division of Medicine, Department of Breast Medical Oncology, Box 56, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Cancer Invest 19:459-66. 2001
    ..v. bolus followed by a continuous infusion of 10 mg/m2/day over 4 days. However, this treatment schedule offers no apparent advantage over the commonly used weekly vinorelbine schedule...
  7. ncbi request reprint Phase I study of vinorelbine and paclitaxel by 3-hour simultaneous infusion with and without granulocyte colony-stimulating factor support in metastatic breast carcinoma
    N K Ibrahim
    Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030 4009, USA
    Cancer 91:664-71. 2001
    ....
  8. ncbi request reprint Doxorubicin-based adjuvant chemotherapy in elderly breast cancer patients: the M.D. Anderson experience, with long-term follow-up
    N K Ibrahim
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Ann Oncol 11:1597-601. 2000
    ..The purpose of this study was to evaluate the clinical outcome of doxorubicin-based adjuvant chemotherapy in elderly breast cancer patients and to compare results in elderly patients with those in younger patients...
  9. ncbi request reprint The evolving role of specific estrogen receptor modulators (SERMs)
    N K Ibrahim
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, USA
    Surg Oncol 8:103-23. 1999
    ....
  10. ncbi request reprint Colitis associated with docetaxel-based chemotherapy in patients with metastatic breast cancer
    N K Ibrahim
    Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Lancet 355:281-3. 2000
    ....
  11. doi request reprint Outcome of metastatic breast cancer in selected women with or without deleterious BRCA mutations
    S Bayraktar
    Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Clin Exp Metastasis 30:631-42. 2013
    ..Our data indicate that BRCA1 carriers diagnosed with MBC have worse outcomes compared to BRCA2 carriers and non-carriers. However, the differences in outcome did not reach statistical significance likely due to small sample sizes...
  12. doi request reprint Defining prognosis for women with breast cancer and CNS metastases by HER2 status
    S Dawood
    Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Ann Oncol 19:1242-8. 2008
    ....
  13. ncbi request reprint US-guided implantation of metallic markers for permanent localization of the tumor bed in patients with breast cancer who undergo preoperative chemotherapy
    B S Edeiken
    Department of Diagnostic Radiology, University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Radiology 213:895-900. 1999
    ..This technique effectively addresses the problem of preoperative localization of the tumor bed in complete or nearly complete response of breast cancer to neoadjuvant chemotherapy...
  14. ncbi request reprint Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trial
    G N Hortobagyi
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 19:3422-33. 2001
    ....
  15. ncbi request reprint Toxicity, immunogenicity, and induction of E75-specific tumor-lytic CTLs by HER-2 peptide E75 (369-377) combined with granulocyte macrophage colony-stimulating factor in HLA-A2+ patients with metastatic breast and ovarian cancer
    James L Murray
    Department of Bioimmunotherapy, M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 8:3407-18. 2002
    ..These results demonstrate that vaccination with E75+ granulocyte macrophage colony-stimulating factor can induce both peptide-specific IFN-gamma and epitope specific CTLs, which lyse HER-2/neu+ tumors in stage IV patients...
  16. ncbi request reprint Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel
    Nuhad K Ibrahim
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Clin Cancer Res 8:1038-44. 2002
    ..This Phase I study examines the toxicity profile, maximum tolerated dose (MTD), and pharmacokinetics of ABI-007...
  17. ncbi request reprint Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study
    Aman U Buzdar
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 13:228-33. 2007
    ..All data were updated through November 2005...
  18. ncbi request reprint Nanoparticle albumin-bound paclitaxel for treatment of metastatic breast cancer
    Mary C Pinder
    University of Texas M D Anderson Cancer Center, Houston, USA
    Drugs Today (Barc) 42:599-604. 2006
    ..The U.S. Food and Drug Administration approved nabP in late 2004 for treatment of metastatic breast cancer after failure of an anthracycline-based regimen...
  19. ncbi request reprint Total RNA yield and microarray gene expression profiles from fine-needle aspiration biopsy and core-needle biopsy samples of breast carcinoma
    W Fraser Symmans
    Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 97:2960-71. 2003
    ..This study compared gene expression profiles derived from fine-needle aspiration biopsy (FNAB) and from core needle biopsy (CBX)...
  20. ncbi request reprint Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial
    Aman U Buzdar
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Clin Cancer Res 8:1073-9. 2002
    ..In this prospective randomized trial, the role of paclitaxel was evaluated in an adjuvant setting to determine its impact on reducing the risk of recurrence in patients with operable breast cancer...
  21. ncbi request reprint Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks
    Marjorie C Green
    The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 424, Houston, TX 77030, USA
    J Clin Oncol 23:5983-92. 2005
    ....
  22. ncbi request reprint Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer
    Aman U Buzdar
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 424, Houston, TX 77030, USA
    J Clin Oncol 23:3676-85. 2005
    ....
  23. ncbi request reprint A detailed evaluation of cardiac toxicity: a phase II study of doxorubicin and one- or three-hour-infusion paclitaxel in patients with metastatic breast cancer
    Sharon H Giordano
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 8:3360-8. 2002
    ..This Phase II study was designed to determine the efficacy and toxicity of combination doxorubicin and paclitaxel as front-line treatment for metastatic breast cancer...
  24. ncbi request reprint Aromatase inhibitors in breast cancer: an overview
    Kadri Altundag
    Department of Breast Medical Oncology, Unit 424, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030 4009, USA
    Oncologist 11:553-62. 2006
    ..These choices should be discussed with the patient, considering the estimated risk for recurrence and other associated comorbid conditions such as osteoporosis and thromboembolism...
  25. ncbi request reprint Radiologic findings in taxane induced colitis
    Harmeet Kaur
    Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Eur J Radiol 66:75-8. 2008
    ..Radiographic changes in patients with taxane colitis are not specific but, in the appropriate context, can suggest the correct diagnosis and guide the patient's management...
  26. ncbi request reprint Leukemogenic effect of chemotherapy in patients with breast carcinoma: is it a real concern?
    Nuhad K Ibrahim
    Cancer 101:1479-81. 2004
  27. ncbi request reprint The impact of immediate breast reconstruction on the technical delivery of postmastectomy radiotherapy
    Sabin B Motwani
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 66:76-82. 2006
    ..To quantify the impact of immediate breast reconstruction on postmastectomy radiation therapy (PMRT) planning...